Saffron (Crocus sativus): The Evidence for Sleep Quality and Sexual Function

What the Clinical Trials Actually Show About One of Integrative Medicine's Most Interesting Botanicals

Yoon Hang Kim, MD, MPH

Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician

Introduction

Few botanicals carry the kind of cross-cultural pedigree that saffron does. Derived from the stigmas of Crocus sativus L., saffron has been used medicinally for over 3,000 years across Persian, Ayurvedic, and traditional Chinese medicine systems. For most of that history, two of its most consistent traditional applications have been as a calming agent for restless sleep and as an aphrodisiac.

What makes saffron particularly interesting from an integrative medicine perspective is that modern clinical research is now catching up to those traditional claims — and the mechanistic picture is surprisingly coherent. The same core bioactive compounds that appear to improve sleep architecture are also implicated in the restoration of sexual function, particularly in the context of antidepressant-induced sexual dysfunction.

This article reviews the current clinical evidence for saffron in two areas that matter deeply to the clients I serve: sleep quality and sexual function. We will also explore why these two domains are not as separate as they might seem — and how saffron's pharmacology may offer a unifying framework.

Saffron's Bioactive Compounds: The Pharmacology

Saffron's therapeutic effects are driven by three major bioactive constituents, each with distinct but complementary mechanisms of action:

Crocin

Crocin is a water-soluble carotenoid responsible for saffron's characteristic deep red color. It is a potent antioxidant — in certain in vitro models, its free radical scavenging capacity exceeds that of vitamin E. Crocin acts primarily through serotonergic and dopaminergic modulation, and animal studies have demonstrated that it increases non-rapid eye movement (NREM) sleep, the deep, restorative phase of the sleep cycle. In preclinical work, the anxiolytic effects of crocins were abolished by the GABA-A benzodiazepine receptor antagonist flumazenil (Pitsikas & Tarantilis, 2020), implicating GABA-A receptor involvement in these effects. Crocin has also demonstrated neuroprotective properties through reduction of glutamate excitotoxicity and enhancement of antioxidant defenses via the Nrf2 pathway.

Safranal

Safranal is a volatile monoterpenoid aldehyde responsible for saffron's distinctive aroma. It is the most lipophilic of saffron's major constituents, which allows it to cross the blood-brain barrier more readily than crocin. Preclinical evidence suggests safranal contributes to anxiolytic and mild sedative effects, though the specific receptor pharmacology in humans requires further characterization. Most positive clinical trials have evaluated standardized whole-saffron extracts rather than isolated constituents.

Crocetin

Crocetin is a smaller, more bioavailable carotenoid related to crocin. It improves blood flow and oxygen delivery to brain tissues. As a downstream metabolite of crocin and a constituent of whole-saffron extracts, crocetin contributes to the overall bioactivity observed in clinical trials of standardized preparations. Direct clinical evidence for isolated crocetin supplementation in sleep remains limited.

The key integrative insight is this: crocin and safranal work through complementary pathways. Crocin provides mood stabilization through serotonergic mechanisms and neuroprotection through antioxidant activity. Safranal contributes to stress resilience through its own preclinically demonstrated anxiolytic effects. Together, they address both the neurochemical and the emotional drivers of poor sleep and sexual dysfunction.

Part I: Saffron and Sleep Quality

The evidence base for saffron as a sleep aid has expanded significantly since 2020, with multiple randomized controlled trials now available.

Key Clinical Trials

Lopresti et al. (2020) — The Foundational Saffron-Sleep Trial

This 28-day, parallel-group, double-blind, randomized controlled trial was the first study specifically designed to evaluate saffron's sleep-enhancing effects. Sixty-three healthy adults aged 18–70 with self-reported poor sleep were randomized to receive either a standardized saffron extract (affron, 14 mg twice daily) or placebo. The primary outcome was the Insomnia Severity Index (ISI). Saffron supplementation was associated with greater improvements in total ISI score, sleep quality, and restorative sleep compared to placebo, with improvements observed across the 28-day treatment period.

Pachikian et al. (2021) — Objective Sleep Measurement with Actigraphy

This Belgian randomized, double-blind, controlled study enrolled 66 subjects with mild to moderate sleep disorder associated with anxiety. Participants received 15.5 mg/day of saffron extract or placebo (maltodextrin) for six weeks. Notably, this trial used actigraphy for objective sleep assessment alongside the PSQI and LSEQ questionnaires. Results demonstrated significant improvements across several subjective sleep measures, while actigraphy showed an increase in time in bed — supporting saffron's sleep-enhancing effects at a lower dose point than several other trials.

Lopresti et al. (2021) — Multi-Dose Sleep, Cortisol, and Melatonin Study

This 28-day, three-arm, parallel-group, double-blind, randomized controlled trial enrolled 120 adults with unsatisfactory sleep. Participants received either 14 mg, 28 mg of a standardized saffron extract (affron), or placebo, taken one hour before bed. This study expanded on the 2020 trial by incorporating salivary cortisol and melatonin measurements alongside subjective sleep quality ratings. Both active doses improved sleep quality. Saffron supplementation was associated with increased evening melatonin concentrations, while cortisol did not differ significantly between groups — providing early biological evidence for saffron's interaction with endogenous melatonin pathways, without supporting a direct HPA axis effect at these doses.

Lang et al. (2025) — The Gut-Sleep-Brain Axis Study

This randomized, double-blind, placebo-controlled pilot study investigated 30 mg/day of a standardized saffron extract (Safr'Inside) in 52 older adults (ages 55–85) with self-reported sleep complaints over four weeks. Results were notable on both subjective and objective measures:

●  Subjective sleep quality: significant improvement (p = 0.02)

●  Sleep efficiency: significant improvement (p = 0.04)

●  Latency to persistent sleep: significant reduction (p = 0.003)

●  Sleep onset latency: significant reduction (p = 0.03)

What made this study particularly interesting was its microbiome analysis. In a subgroup (n = 26), saffron supplementation was associated with significant increases in SCFA-producing bacteria including Faecalibacterium, Roseburia, and Prevotella, while decreasing Dialister and Turicibacter. Changes in these microbial populations correlated with objective sleep parameters — wake duration, latency to persistent sleep, and wake-after-sleep-onset. This is among the first studies to associate saffron-induced microbiome shifts with sleep improvements. Because the analyses were correlational, they suggest — but do not prove — that microbial changes mediate saffron's effect on sleep.

Schuster et al. (2025) — Dose-Ranging Insomnia Trial

This three-arm, randomized, double-blind, placebo-controlled trial enrolled 165 adults with moderate insomnia. Participants received either 30 mg, 20 mg of a standardized saffron extract (Safr'Inside), or placebo for four weeks. Both active doses improved sleep quality relative to placebo, with additional benefits observed for stress and psychological outcomes.

Lopresti et al. (2025) — Saffron for Mood and Sleep

This 12-week, parallel-group, randomized, double-blind, placebo-controlled trial examined 28 mg/day of saffron extract (affron) in 202 adults with subclinical depressive symptoms. The trial's clearest finding was improvement in depressive symptoms; overall secondary sleep outcomes did not show significant between-group differences, though exploratory analyses suggested sleep benefits among participants with greater baseline sleep disturbance. This trial reinforces the mechanistic link between mood regulation and sleep for a subset of the population, while tempering the conclusion that saffron reliably improves sleep in adults selected primarily for mood symptoms.

Proposed Mechanisms for Sleep Improvement

●  Serotonin–melatonin pathway: Saffron's serotonergic activity may support endogenous melatonin production via the serotonin-to-melatonin conversion pathway, facilitating circadian entrainment. A preclinical study (De la Fuente Muñoz et al., 2023) demonstrated that saffron extract supplementation increased melatonin synthesis by modulating the kynurenine pathway, shunting more tryptophan toward serotonin and subsequently melatonin rather than kynurenine metabolites.

●  GABAergic modulation: Preclinical evidence implicates GABA-A receptor involvement in crocins' anxiolytic effects (Pitsikas & Tarantilis, 2020), which may translate to promoting relaxation and sleep onset. Whether this represents a direct positive allosteric modulation, indirect modulation of GABA release, or another mechanism remains under investigation.

●  NMDA receptor antagonism: Saffron constituents exhibit NMDA receptor antagonism in preclinical models, which has been proposed to reduce cortical hyperarousal — a hypothesized driver of insomnia.

●  Gut-brain axis modulation: As suggested by the Lang et al. study, saffron may shift the gut microbiome toward SCFA-producing taxa, an association that may reflect an indirect pathway to improved sleep — though causality remains to be established.

●  Anxiolytic effects: By reducing anxiety through serotonergic and GABAergic mechanisms, saffron may address the psychological component of insomnia — particularly relevant for clients with comorbid anxiety.

Part II: Saffron and Sexual Function

The evidence for saffron in sexual dysfunction is more established and clinically mature, with particular strength in the management of antidepressant-induced sexual dysfunction — one of the most common and undertreated complaints in clinical practice.

SSRI-Induced Sexual Dysfunction in Men

Modabbernia et al. (2012)

This randomized, double-blind, placebo-controlled trial assessed saffron (30 mg/day as 15 mg BID for four weeks) in men with fluoxetine-induced sexual dysfunction. Using the International Index of Erectile Function (IIEF), saffron significantly improved erectile function and intercourse satisfaction compared to placebo. The speed of response was notable — measurable improvements were observed by the second week.

SSRI-Induced Sexual Dysfunction in Women

Kashani et al. (2013)

Using the same dosing protocol (30 mg/day for four weeks), this randomized, double-blind, placebo-controlled trial in women with fluoxetine-induced sexual dysfunction found significant improvements in total Female Sexual Function Index (FSFI) score, arousal, lubrication, and pain. Desire, satisfaction, and orgasm domains did not reach statistical significance in this trial.

Female Sexual Dysfunction (Non-SSRI)

Kashani et al. (2022)

A three-center, double-blind, randomized, placebo-controlled trial investigated saffron capsules for female sexual dysfunction independent of antidepressant use, in women with severe sexual dysfunction, dosed at 30 mg/day for six weeks. Results supported saffron as a safe and potentially effective option, consistent with its traditional use as an aphrodisiac across multiple cultures.

Erectile Dysfunction (General)

Maleki-Saghooni et al. (2018) — Systematic Review and Meta-Analysis

This meta-analysis of clinical trials on saffron and erectile dysfunction found significant positive effects across four dimensions of the IIEF: erectile function (MD = 5.36, p < 0.01), orgasmic function (MD = 1.12, p = 0.007), overall satisfaction (MD = 1.23, p = 0.005), and intercourse satisfaction (MD = 2.18, p < 0.01). The pooled estimate for sexual desire was MD = 0.78 (95% CI −0.01 to 1.57); because the confidence interval crossed zero, this outcome should not be considered clearly statistically significant. Proposed mechanisms include nitric oxide enhancement and modulation of opioid signaling.

Meta-Analytic Evidence Across Genders

Ranjbar & Ashrafizaveh (2019)

A systematic review and meta-analysis published in Avicenna Journal of Phytomedicine comprising five studies and 173 participants found a statistically significant positive effect of saffron on sexual dysfunction overall (standardized mean difference = 0.811, 95% CI 0.356–1.265) and across individual subscales (standardized mean difference = 0.493, 95% CI 0.261–0.724). The analysis included studies of both men and women.

Proposed Mechanisms for Sexual Function

●  Dopaminergic enhancement: Preclinical evidence suggests crocin supports dopamine neurotransmission, which is critical for sexual desire and arousal. SSRIs suppress dopaminergic pathways as a downstream consequence of excessive serotonergic tone. Dopaminergic enhancement is a leading mechanistic hypothesis for saffron's role in counteracting SSRI-induced sexual dysfunction, though direct clinical evidence linking this specific mechanism to the observed clinical improvements remains largely preclinical.

●  Nitric oxide pathway: Saffron enhances nitric oxide synthesis in preclinical models, supporting vascular engorgement — the physiological basis of erectile function and female arousal.

●  Anxiolysis: The anxiolytic effects of saffron's active constituents may reduce performance anxiety and psychogenic inhibition of sexual response.

●  Anti-inflammatory and antioxidant activity: Crocin and crocetin reduce oxidative stress in vascular endothelium in preclinical models, which may support blood flow to reproductive tissues independently of the nitric oxide pathway.

The Integrative Connection: Why Sleep and Sexual Health Are Linked

From an integrative medicine perspective, it is no coincidence that the same botanical addresses both sleep and sexual function. These are not separate pathways — they share common neurochemical infrastructure:

●  Serotonin is the precursor to melatonin (sleep) and a modulator of sexual arousal and orgasm.

●  GABA promotes sleep onset and reduces performance anxiety.

●  Dopamine drives both wakeful alertness and sexual desire.

●  Cortisol and the HPA axis — when dysregulated — suppress both sleep architecture and libido simultaneously.

Clients who present with both poor sleep and diminished sexual function often share upstream neurochemical dysregulation. Saffron's pharmacology touches multiple nodes in this shared network, which is why it may be particularly valuable for clients who carry both complaints — a population that, in my clinical experience, is far more common than most practitioners appreciate.

The gut-brain axis findings from Lang et al. (2025) add another dimension to this integrative framework. Saffron-induced shifts in SCFA-producing bacteria correlated with sleep improvements in that study. Whether similar microbiome shifts contribute to saffron's effects on sexual function is an interesting hypothesis, but it remains untested — the Lang study did not evaluate sexual outcomes.

Practical Considerations: Dosing, Safety, and Quality

Dosing

●  General sleep support: 14–30 mg/day of standardized saffron extract (affron or Safr'Inside). The 14 mg lower bound reflects the lowest arm tested in Lopresti et al. 2021; most sleep trials used 15.5–30 mg/day.

●  SSRI-induced sexual dysfunction: 30 mg/day (15 mg BID), typically for a minimum of four weeks.

●  General sexual dysfunction: 30 mg/day for 4–12 weeks.

●  Mood support (with possible secondary sleep benefits): 28–30 mg/day for 4–12 weeks.

Safety and Tolerability

Across the clinical trials reviewed, saffron at doses of 14–30 mg/day demonstrates a favorable safety profile. Reported adverse effects are generally mild and transient — most commonly gastrointestinal discomfort, dry mouth, or mild headache. A 2025 meta-analysis directly comparing saffron with SSRIs for depression and anxiety (Shafiee et al., 2025) found fewer adverse events with saffron (absolute risk difference −0.06; 95% CI −0.09 to −0.04; I² = 0%). A dedicated 2026 systematic review of saffron adverse events (Hasheminasab et al., 2026), covering 102 clinical trials, concluded that saffron is generally well tolerated, with gastrointestinal effects the most frequent and usually minor and self-limiting; it also cautioned that safety data for higher-dose and prolonged medicinal use remain limited. Long-term safety data beyond 12 weeks are limited.

Quality Matters: Extract Standardization

Not all saffron supplements are equivalent. The clinical trials reviewed predominantly used standardized extracts with defined concentrations of characteristic saffron bioactive markers. Safranal is particularly volatile and degrades rapidly during conventional extraction. Encapsulation and extraction technologies used in preparations such as Safr'Inside and affron are designed to preserve safranal bioavailability. When recommending saffron to clients, I emphasize third-party tested, standardized extracts over culinary-grade saffron powder, which may contain insufficient concentrations of the active constituents.

The Bottom Line

Saffron is one of the more interesting botanicals in the integrative medicine toolkit — with legitimate randomized-trial evidence for sleep quality in adults with sleep complaints, and mature clinical evidence for sexual function, particularly SSRI-associated sexual dysfunction. The evidence base is not perfect: some findings depend on exploratory analyses, some mechanistic claims outrun the clinical data, and the sexual function trials have been concentrated in Iranian populations. Still, the overall pattern is coherent.

For integrative practitioners, saffron offers something especially valuable: a single, generally well-tolerated intervention that addresses two complaints that frequently co-occur and share common neurochemical roots. That kind of mechanistic efficiency is exactly what good integrative medicine should look for.

As always, supplementation should be guided by a comprehensive clinical evaluation and individualized to the client's full picture — not used as a standalone intervention. But for the right client, at the right dose, with the right extract, saffron deserves a serious place in the conversation.

References

1. Lopresti AL, Smith SJ, Metse AP, Drummond PD. Effects of saffron on sleep quality in healthy adults with self-reported poor sleep: a randomized, double-blind, placebo-controlled trial. J Clin Sleep Med. 2020;16(6):937-947. doi:10.5664/jcsm.8376

2. Pachikian BD, Copine S, Suchareau M, Deldicque L. Effects of saffron extract on sleep quality: a randomized double-blind controlled clinical trial. Nutrients. 2021;13(5):1473. doi:10.3390/nu13051473

3. Lopresti AL, Smith SJ, Drummond PD. An investigation into an evening intake of a saffron extract (affron) on sleep quality, cortisol, and melatonin concentrations in adults with poor sleep: a randomised, double-blind, placebo-controlled, multi-dose study. Sleep Med. 2021;86:7-18. doi:10.1016/j.sleep.2021.08.001

4. Lang L, Ditton A, Stanescu A, et al. A standardised saffron extract improves subjective and objective sleep quality in healthy older adults with sleep complaints: results from the Gut-Sleep-Brain Axis randomised, double-blind, placebo-controlled pilot study. Food Funct. 2025;16(17):6817-6832. doi:10.1039/d5fo00917k

5. Schuster J, Mundhenke C, Nordsieck H, et al. Effect of a saffron extract on sleep quality in adults with moderate insomnia: a decentralized, randomized, double-blind, placebo-controlled trial. Sleep Med X. 2025;10:100147. doi:10.1016/j.sleepx.2025.100147

6. Lopresti AL, Smith SJ, Marx W, Díez-Municio M, Morán-Valero MI. An examination into the effects of a saffron extract (affron) on mood and general wellbeing in adults experiencing low mood: a randomized, double-blind, placebo-controlled trial. J Nutr. 2025;155(7):2300-2311. doi:10.1016/j.tjnut.2025.05.024

7. Modabbernia A, Sohrabi H, Nasehi AA, et al. Effect of saffron on fluoxetine-induced sexual impairment in men: randomized double-blind placebo-controlled trial. Psychopharmacology. 2012;223(4):381-388. doi:10.1007/s00213-012-2729-6

8. Kashani L, Raisi F, Saroukhani S, et al. Saffron for treatment of fluoxetine-induced sexual dysfunction in women: randomized double-blind placebo-controlled study. Hum Psychopharmacol. 2013;28(1):54-60. doi:10.1002/hup.2282

9. Kashani L, Aslzadeh S, Shokraee K, et al. Crocus sativus (saffron) in the treatment of female sexual dysfunction: a three-center, double-blind, randomized, and placebo-controlled clinical trial. Avicenna J Phytomed. 2022;12(3):257-268. doi:10.22038/ajp.2022.19714

10. Maleki-Saghooni N, Mirzaeii K, Hosseinzadeh H, Sadeghi R, Irani M. A systematic review and meta-analysis of clinical trials on saffron (Crocus sativus) effectiveness and safety on erectile dysfunction and semen parameters. Avicenna J Phytomed. 2018;8(3):198-209. doi:10.22038/ajp.2017.20563.1784

11. Ranjbar H, Ashrafizaveh A. Effects of saffron (Crocus sativus) on sexual dysfunction among men and women: a systematic review and meta-analysis. Avicenna J Phytomed. 2019;9(5):419-427. doi:10.22038/ajp.2019.12686

12. Shafiee A, Jafarabady K, Seighali N, Mohammadi I, Rajai Firouz Abadi S, Soltani Abhari F, Bakhtiyari M. Effect of saffron versus selective serotonin reuptake inhibitors (SSRIs) in treatment of depression and anxiety: a meta-analysis of randomized controlled trials. Nutr Rev. 2025;83(3):e751-e761. doi:10.1093/nutrit/nuae076

13. Pitsikas N, Tarantilis PA. The GABA-A-benzodiazepine receptor antagonist flumazenil abolishes the anxiolytic effects of the active constituents of Crocus sativus L. crocins in rats. Molecules. 2020;25(23):5647. doi:10.3390/molecules25235647

14. El Midaoui A, Ghzaiel I, et al. Saffron (Crocus sativus L.): a source of nutrients for health and for the treatment of neuropsychiatric and age-related diseases. Nutrients. 2022;14(3):597. doi:10.3390/nu14030597

15. De la Fuente Muñoz M, Román-Carmena M, Amor S, et al. Effects of supplementation with the standardized extract of saffron (affron) on the kynurenine pathway and melatonin synthesis in rats. Antioxidants. 2023;12(8):1619. doi:10.3390/antiox12081619

16. Hasheminasab FS, Hajimonfarednejad M, Najibi SM, Hashempur MH. Adverse events of saffron (Crocus sativus L.): systematic review of current evidence. Health Sci Rep. 2026;9(5):e72212. doi:10.1002/hsr2.72212

In health,

Yoon Hang Kim, MD, MPH

About Dr. Kim

Yoon Hang Kim, MD, MPH is a board-certified physician with over 20 years of clinical experience. A graduate of the University of Arizona Center for Integrative Medicine's Osher Fellowship under Dr. Andrew Weil, Dr. Kim holds certifications in preventive medicine, medical acupuncture, and integrative and holistic medicine. He specializes in low-dose naltrexone (LDN), autoimmune conditions, chronic pain syndromes, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome (MCAS), and mold-related illness. He is the author of three books and more than 20 peer-reviewed articles.

Professional: www.yoonhangkim.com 

Clinical: www.directintegrativecare.com